Dr. Reddy’s Laboratories Limited (NYSE: RDY) disclosed Wednesday that it has unveiled Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial agreed by the U.S. FDA.
The firm revealed the INVANZ brand and generic market had U.S. sales of nearly $205 million MAT for the latest twelve months completed in March 2021. Dr. Reddy’s Ertapenem for Injection, 1 g/vial, is accessible in packs of 10 vials per carton. Additionally, INVANZ is a trademark of Merck and Co., Inc.
Dr. Reddy’s Laboratories is excited to launch the product to market at this time. The firm is expanding its strategic collaboration with Gland Pharma. Gland Pharma has cooperated with the squad at Dr. Reddy’s which has allowed the implementation of this unveiling. The collaboration of Dr. Reddy and Gland Pharma has brought close the skilled advertising and delivery abilities.
Gland Pharma has a special API supply agreement for this product and a devoted business facility in Hyderabad for Ertapenem Injection. Both the firms will grow bulk consumption of this devoted Penem facility with the introduction of this invention.